文献速递姑息放疗与转移瘤胸部肿瘤放疗头颈部肿瘤放疗

二甲双胍作为实体瘤放射增敏剂效果的系统综述

Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-02-10

该系统综述按照PRISMA标准纳入2010至2022年间发表的临床试验、系统综述和观察性研究,分析二甲双胍联合放疗对实体瘤患者生存(OS、PFS、DFS、DMFS)和反应(ORR)的影响。共纳入16项研究,最常见为前列腺癌(5项)。二甲双胍联合放疗在前列腺、肝脏和妇科肿瘤中显示出生存和反应方面的一致获益,但在肺癌、直肠癌和头颈癌中获益存疑且结果矛盾。作者认为二甲双胍联合放疗是肿瘤学中最有前景的在研治疗之一,真实世界研究观察到的获益使得有必要开展专门评估其临床应用的临床试验。

要点

  • 二甲双胍联合外照射放疗在前列腺癌、肝癌和妇科肿瘤中显示生存和反应方面的一致获益。
  • 前列腺癌中获益最大,OS和SLE均观察到获益。
  • 肺癌、直肠癌和头颈癌中获益存疑且结果矛盾。

核心结论

  • 二甲双胍联合放疗治疗实体瘤是肿瘤学中最有前景的在研治疗之一。
  • 真实世界研究观察到的获益使得有必要开展专门评估其临床应用的临床试验。

研究设计与样本

  • 按照PRISMA标准进行的系统综述,纳入临床试验、系统综述和观察性研究,研究发表于2010年至2022年间。
  • 共纳入16项研究,最常见肿瘤为前列腺癌(5项研究)。
  • 所有研究均给予外照射放疗,其中两项研究还给予近距离放疗。

主要发现

  • 二甲双胍联合放疗在前列腺、肝脏和妇科肿瘤中显示出生存和反应方面的一致获益。
  • 其余分析的肿瘤(肺癌、直肠癌和头颈癌)中获益存疑且结果矛盾。
  • 前列腺肿瘤中观察到最大获益,OS和SLE均如此。

关键数值与推荐

  • 分析结局包括生存指标(OS、PFS、DFS、DMFS)和反应指标(ORR),比较接受二甲双胍与未接受二甲双胍的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin is an antidiabetic drug that has shown its benefit in increasing the effect of radiotherapy in the treatment of solid tumors in preclinical studies. The objective of this systematic review is to study the effect of metformin as a radiosensitizer in studies carried out in clinical practice. METHODS: Systematic review carried out according to PRISMA criteria of clinical trials, systematic reviews and observational studies focused on the influence of metformin as a radiosensitizer in solid tumors. The studies were published between the years 2010 and 2022. The results of the studies have been analyzed in terms of survival (OS, PFS, DFS, DMFS) and response (ORR) between patients treated with metformin and without it. RESULTS: A total of 16 studies have been found in the literature (the most frequent tumor was prostate cancer, 5 studies). External radiotherapy was administered in all the studies and in two of them to greater brachytherapy. The use of metformin with radiotherapy showed a consistent benefit in terms of survival and response in tumors of prostate, hepatic and gynecological origin. The benefit in the rest of the tumors analyzed (lung, rectal, and head and neck cancer) is doubtful, and the results are contradictory. The greatest benefits were observed in prostate tumors both in OS and SLE. CONCLUSIONS: The use of metformin in combination with radiotherapy in solid tumors is one of the most promising treatments under development in oncology. The benefit observed in real-life studies makes it necessary to develop clinical trials that specifically evaluate its use in clinical practice in the future.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Portillo EGD, Olivares-Hernández A, Corral-Gudino L, et al. Evaluation of the effect of metformin as a radiosensitiser in solid tumours: A systematic review. Clin Transl Radiat Oncol. 2025. PMID: 40028423. doi:10.1016/j.ctro.2025.100930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。